Rosuvastatin to atorvastatin conversion
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin to Atorvastatin Conversion: Efficacy and Safety Insights
Efficacy in Reducing LDL-C Levels
Comparative Efficacy in Hypercholesterolemia
Several studies have compared the efficacy of rosuvastatin and atorvastatin in reducing low-density lipoprotein cholesterol (LDL-C) levels. Rosuvastatin at lower doses (5 mg) has been shown to be more effective than atorvastatin (10 mg) in reducing small dense LDL-C levels in Japanese patients with type 2 diabetes mellitus. Additionally, rosuvastatin 10 mg was found to reduce LDL-C levels more significantly than atorvastatin 20 mg in high-risk patients with hypercholesterolemia, achieving greater LDL-C goal attainment .
High-Dose Comparisons
In high-risk patients, rosuvastatin 40 mg demonstrated superior LDL-C reduction compared to atorvastatin 80 mg, with a higher percentage of patients achieving LDL-C goals. This was further supported by the VOYAGER meta-analysis, which indicated that each dose of rosuvastatin is approximately 3-3.5 times more potent than atorvastatin in reducing LDL-C and non-HDL-C levels.
Impact on Coronary Atherosclerotic Plaques
Plaque Regression
A meta-analysis comparing the effects of rosuvastatin and atorvastatin on coronary atherosclerotic plaques found that rosuvastatin was more effective in reducing total atheroma volume and percent atheroma volume, and in improving lumen volume. This suggests that rosuvastatin may offer superior benefits in the regression of coronary plaques compared to atorvastatin.
Safety and Side Effects
Long-Term Safety
In a long-term study involving adults with coronary artery disease, both rosuvastatin and atorvastatin showed comparable efficacy for the composite outcome of all-cause death, myocardial infarction, stroke, or any coronary revascularization over three years. However, rosuvastatin was associated with a higher incidence of new-onset diabetes mellitus requiring antidiabetics and cataract surgery compared to atorvastatin.
Renal Effects
In patients with diabetes and progressive renal disease, atorvastatin 80 mg demonstrated more renoprotective effects compared to rosuvastatin 10 mg and 40 mg, despite rosuvastatin's superior lipid-lowering capabilities. This indicates that atorvastatin may be preferable for patients with chronic kidney disease.
Cost-Effectiveness
Economic Considerations
Rosuvastatin has been found to be more cost-effective than atorvastatin in both the US and UK settings, particularly in achieving LDL-C goals and improving other lipid parameters . This economic advantage, combined with its efficacy, makes rosuvastatin a compelling option for high-risk patients.
Conclusion
Switching from atorvastatin to rosuvastatin can offer significant benefits in terms of LDL-C reduction and plaque regression, particularly at lower doses. However, the choice between these statins should consider individual patient profiles, including the risk of diabetes and renal conditions. Both statins are effective, but rosuvastatin may provide superior lipid-lowering efficacy and cost-effectiveness, while atorvastatin may offer better renal protection.
Sources and full results
Most relevant research papers on this topic